Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782

  title={Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782},
  author={Hilde Lavreysen and Xavier Langlois and Abdel Ahnaou and Wilhelmus H.I.M. Drinkenburg and Paula te Riele and Ilse Biesmans and Ilse van der Linden and Luc Peeters and Anton A Megens and Cindy Wintmolders and Jos{\'e} Mar{\'i}a Cid and Andr{\'e}s A. Trabanco and Jos{\'e} Ignacio Andr{\'e}s and Frank Matthias Dautzenberg and Robert Johannes L{\"u}tjens and Gregor James Macdonald and John R. Atack},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  pages={514 - 527}
Modulation of the metabotropic glutamate type 2 (mGlu2) receptor is considered a promising target for the treatment of central nervous system diseases such as schizophrenia. Here, we describe the pharmacological properties of the novel mGlu2 receptor positive allosteric modulator (PAM) 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) and its radioligand [3H]JNJ-40068782. In guanosine 5′-O-(3-[35S]thio)triphosphate binding, JNJ-40068782 produced a… 

Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor

The data show that JNJ‐40411813 is an interesting candidate to explore the therapeutic potential of mGlu2 PAMs, in in vivo rodents experiments as well as in clinical studies.

Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor

Findings indicate that TASP0433864 is a selective mGlu2 receptor PAM with antipsychotic activity, and the attenuation of excess glutamatergic neurotransmission may be involved in the action of TASp04338 64.

Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.

The design and synthesis of a radiolabeled negative allosteric modulator (NAM) for mGlu2 PET tracer development based on a quinoline 2-carboxamide scaffold is reported, and [11C]QCA is a chemical probe that provides the basis for the development of a new generation mGLU2PET tracers.

PET imaging studies to investigate functional expression of mGluR2 using [11C]mG2P001

Positive allosteric modulation of mGluR2 was investigated via the in vivo positron emission tomography (PET) imaging and quantitative analysis of [11C]mG2P001 in non-human primates (NHPs) further validated the characteristics of [ 11C]MG 2P001 as an imaging ligand for mGLUR2.

mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats

The present rodent findings suggest that mGluR2 positive allosteric modulation has therapeutic potential based on its superior long term efficacy over agonists in psychiatric disorders, particularly of those commonly occurring with REM sleep overdrive.

Synthesis and preliminary studies of a novel negative allosteric modulator [11C]QCA for imaging of metabotropic glutamate receptor 2

Metabotropic glutamate 2 receptors (mGlu2) are involved in the pathogenesis of several CNS disorders and neurodegenerative diseases. Pharmacological modulation of this target represents a potential



Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.

It is proposed that this allosteric binding site defines a pocket that is different from the orthosteric site located in the amino terminal domain at hmGluR2, and is also observed to a greater extent on the concentration-response curves to selective hmR2/3 agonists.

A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity

The finding that the effects of an orthosteric mGlu2/3 receptor agonist in these models can be mimicked by a selective allosteric potentiator of mGLU2 suggests that these effects are mediated by the mGlam2 receptor subtype.

Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice

Results indicate that BINA is a selective mGluR2 positive allosteric modulator and provide further support for the growing evidence that selective allosterics potentiators of mGLUR2 mimic many of the in vivo actions of m GluR 2/3 agonists that may predict therapeutic utility of these compounds.

[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists.

The high affinity and selectivity of [(3)H]R214127 for mGlu1 receptors renders this compound the ligand of choice to study the native mGLU1 receptor in brain.

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

The data indicate mGlu2 receptor potentiators have a unique use-dependent effect on presynaptic glutamate release, and show efficacy in several mGLU2/3-sensitive animal models of psychiatric disorders.

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice

The activation of bothmGlu2 and mGlu3 receptors by LY354740 appears to be required for anxiolytic-like activity in the EPM test in mice, and these studies serve as a foundation for additional studies on underlying circuits, brain structures, and receptor subtypes involved in the anxiety-related actions of mGLU receptor active agents, and the design of future drugs for anxiety disorders in humans.

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu

The results indicate that the novel mGlu2-positive allosteric modulator THIIC has robust activity in models used to predict anxiolytic/antidepressant efficacy, substantiating, at least with this molecule, differentiation in the biological impact of mGLU2 potentiation versus mGlam2/3 orthosteric agonism.

Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

The data demonstrate that the antipsychotic-like effects of the mGlu2/3 receptor agonist LY404039 in psychostimulant models of psychosis are mechanistically distinct from those of atypical antipsychotics drugs and are dependent on functional mGLU2 and notmGlu3 receptors.

LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.

The antipsychotic efficacy of LY-2140023 was confirmed in a randomized, placebo-controlled, phase II clinical trial in patients with schizophrenia, and it lacked the extrapyramidal and metabolic side effects that are commonly observed with the majority of currently approved antipsychotics.